Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance
Presented By:
Hillary Stires, PhD - Postdoctoral Fellow, Georgetown University Lombardi Comprehensive Cancer Center
Speaker Biography:
Dr. Hillary Stires is a postdoctoral fellow training in the Tumor Biology program funded through a T32 Ruth L. Kirschstein National Research Service Award at Georgetown University Lombardi Comprehensive Cancer Center under the mentorship of Dr. Rebecca Riggins. Dr. Stires received her PhD from Rutgers University in Endocrinology and Animal Biosciences and has always been interested in how steroid hormones (specifically estrogen) influence breast cancer development. In Dr. Riggins lab, Hillary's work focuses on the endocrine resistance in breast cancer.
Webinar:
Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance
Webinar Abstract:
Breast cancers are classified into three main subtypes according to their receptor status: estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), and triple negative. These classifications provide information about the biology of the disease and help clinicians determine which treatments to use for patients. Targeted therapy for HER2+ breast cancer, including trastuzamab and pertuzamab, and for ER+ breast cancer, including Tamoxifen and aromatase inhibitors, have drastically improved survival outcomes for patients with these disease subtypes. However, when tumors are both HER2+ and ER+, treatment decisions and outcomes are less clear. HER2+/ER+ breast cancers treated with HER2 targeted therapies do not respond as well as HER2+/ER-negative tumors. Our lab is interested in understanding the biology behind these differences in response as well as better defining treatment options for HER2+/ER+ breast cancer. We have established long-term estrogen deprived (LTED) cell models of HER2+/ER+ breast cancer utilizing phenol-red free media as a surrogate for aromatase inhibitor treatment and Fulvestrant (a selective estrogen receptor degrader) resistant cell lines using increasing doses of Fulvestrant over time. We are testing combination therapy over different time courses then measure proliferation and targets of downstream signaling including protein phosphorylation by western blot and gene transcription by qRTPCR. Ultimately, these results will help inform clinicians about the most effective treatment for patients with HER2+/ER+ breast cancer.
Learn more about the Gibco Cell Culture Heroes program and watch more webinars just like this one by visiting https://www.thermofisher.com/us/en/home/references/gibco-cell-culture-basics/cell-culture-heroes.html
Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/ms/webinar/optimizing-treatment-options-her2-er-breast-cancer-using-models-endocrine-resistance)
2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/ms/webinar/optimizing-treatment-options-her2-er-breast-cancer-using-models-endocrine-resistance)
3. Click Here to get your PACE credits (Expiration date – December 13, 2020 09:00 AM): https://www.labroots.com/credit/pace-credits/3129/third-party
LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc
Видео Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance канала Labroots
Hillary Stires, PhD - Postdoctoral Fellow, Georgetown University Lombardi Comprehensive Cancer Center
Speaker Biography:
Dr. Hillary Stires is a postdoctoral fellow training in the Tumor Biology program funded through a T32 Ruth L. Kirschstein National Research Service Award at Georgetown University Lombardi Comprehensive Cancer Center under the mentorship of Dr. Rebecca Riggins. Dr. Stires received her PhD from Rutgers University in Endocrinology and Animal Biosciences and has always been interested in how steroid hormones (specifically estrogen) influence breast cancer development. In Dr. Riggins lab, Hillary's work focuses on the endocrine resistance in breast cancer.
Webinar:
Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance
Webinar Abstract:
Breast cancers are classified into three main subtypes according to their receptor status: estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), and triple negative. These classifications provide information about the biology of the disease and help clinicians determine which treatments to use for patients. Targeted therapy for HER2+ breast cancer, including trastuzamab and pertuzamab, and for ER+ breast cancer, including Tamoxifen and aromatase inhibitors, have drastically improved survival outcomes for patients with these disease subtypes. However, when tumors are both HER2+ and ER+, treatment decisions and outcomes are less clear. HER2+/ER+ breast cancers treated with HER2 targeted therapies do not respond as well as HER2+/ER-negative tumors. Our lab is interested in understanding the biology behind these differences in response as well as better defining treatment options for HER2+/ER+ breast cancer. We have established long-term estrogen deprived (LTED) cell models of HER2+/ER+ breast cancer utilizing phenol-red free media as a surrogate for aromatase inhibitor treatment and Fulvestrant (a selective estrogen receptor degrader) resistant cell lines using increasing doses of Fulvestrant over time. We are testing combination therapy over different time courses then measure proliferation and targets of downstream signaling including protein phosphorylation by western blot and gene transcription by qRTPCR. Ultimately, these results will help inform clinicians about the most effective treatment for patients with HER2+/ER+ breast cancer.
Learn more about the Gibco Cell Culture Heroes program and watch more webinars just like this one by visiting https://www.thermofisher.com/us/en/home/references/gibco-cell-culture-basics/cell-culture-heroes.html
Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/ms/webinar/optimizing-treatment-options-her2-er-breast-cancer-using-models-endocrine-resistance)
2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/ms/webinar/optimizing-treatment-options-her2-er-breast-cancer-using-models-endocrine-resistance)
3. Click Here to get your PACE credits (Expiration date – December 13, 2020 09:00 AM): https://www.labroots.com/credit/pace-credits/3129/third-party
LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc
Видео Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance канала Labroots
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Estrogen Receptors & HER2/neu Receptors in Breast Cancer (a TUTORIAL from Oster Oncology)](https://i.ytimg.com/vi/BojDeabPQTs/default.jpg)
![Treatment Options for ER/PR Positive Breast Cancers](https://i.ytimg.com/vi/4OxxQZUcVeg/default.jpg)
![Her-2 Positive Breast Cancer](https://i.ytimg.com/vi/KPUM5AbLsRo/default.jpg)
![The HER Pathway and Cancer](https://i.ytimg.com/vi/Q3Tzc3jGt3U/default.jpg)
![HER2-Positive Breast Cancer—Reduce Your Risk of Recurrence | Access Health](https://i.ytimg.com/vi/ce_3mZh-rQo/default.jpg)
![Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms](https://i.ytimg.com/vi/thy9g4ITdxU/default.jpg)
![ER+ Breast Cancer Case Panel Discussion | 2022 Best of Breast Conference](https://i.ytimg.com/vi/A8jj2uktxjU/default.jpg)
![Gastric Cancer: Update on First-Line Therapies](https://i.ytimg.com/vi/lA5Fttcm4u8/default.jpg)
![Adjuvant therapy for early stage ER-positive, HER2-negative invasive breast cancer](https://i.ytimg.com/vi/s1gsCFJVrWk/default.jpg)
![Diseases of Breast: Part 4: Breast carcinoma- risk factors, pathogenesis & classification](https://i.ytimg.com/vi/Q1oukQiQS84/default.jpg)
![How do monoclonal antibodies work? Rituximab, infliximab, adalimumab and others](https://i.ytimg.com/vi/h6sGMaf6Yew/default.jpg)
![Instrument Qualification for a Quality Management System](https://i.ytimg.com/vi/PZGkLHTDyt0/default.jpg)
![Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020](https://i.ytimg.com/vi/AsyMNYVB680/default.jpg)
![Cell Culture (Attached Cell)](https://i.ytimg.com/vi/7d_kDu-P964/default.jpg)
![Tale of amyloid filaments in neurodegenerative diseases](https://i.ytimg.com/vi/0ZYvpdpE5Ps/default.jpg)
![Hormone Receptor-Positive and HER2-Positive Breast Cancer: A Medical Update](https://i.ytimg.com/vi/mRtsk861nfg/default.jpg)
![Solve Every Hereditary Disorder Case for All Types of Genetic Variation](https://i.ytimg.com/vi/ZcfuuOHTL0U/default.jpg)
![Expert Perspectives: CDK 4/6 Inhibitors for ER+ Breast Cancer: Current Data and Clinical Use](https://i.ytimg.com/vi/zgkKERWfW_w/default.jpg)
![Primary and Acquired Resistance to Cancer Immunotherapy](https://i.ytimg.com/vi/XIWTVJf9cak/default.jpg)
![Having radiotherapy for breast cancer - Part Two: Having Treatment](https://i.ytimg.com/vi/4SSTa9rMjrc/default.jpg)